| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.16 | 0.05 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.05 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.05 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.06 |